Orthopediatrics Corp (KIDS) is an industry-leading medical device company primarily focused on developing treatments for children and adolescents with orthopedic conditions. Headquartered in Warsaw, Indiana, Orthopediatrics Corp. was founded in 2007 with the sole aim to provide the highest quality orthopedic implants and instruments specifically designed for pediatric patients, in an era when the sector was mainly focused on adults.
The company's commitment towards their mission, "Helping children with orthopedic conditions lead healthy, active lives", is reflected in their diversified product portfolio, with over 35 product systems developed exclusively for the pediatric orthopedic market. These products cover a wide spectrum of needs, targeting trauma and deformity, scoliosis, sports medicine and other clinical specialties.
Orthopediatrics Corp has cemented its position globally, with strong distribution networks in over 40 countries. Partnering with leading healthcare professionals, they have pioneered innovative solutions for complex medical conditions with their cutting-edge products, revolutionizing pediatric orthopedic care. The company's continuous focus on improvement, research and patient care has allowed them to achieve this influential status in a niche market.
Their success traces back to the dedicated team of experienced management, innovative engineers, adept clinicians and a skilled sales force who have collective years of experience and expertise in the orthopedic industry. This team's commitment to uphold the highest standards of quality, ethics and patient care is fundamentally structured on benefiting younger patients.
Moreover, as part of its commitment towards improving pediatric orthopedic care, the corporation actively invests in clinical education. Orthopediatrics Corp. offers a range of educational activities, from resident programs and surgeon fly-ins to hands-on cadaver courses, aiming to educate and diligently provide precise solutions to pediatric orthopedic issues.
In addition to their ethical product development, the corporation is part of numerous philanthropic initiatives such as funding non-profits that sponsor pediatric surgeries, and sponsoring medical mission trips. This expands their corporate social responsibility while also broadening the impact of their mission.
Over the years, Orthopediatrics Corp. has demonstrated a solid growth trajectory, a trend backed up by strong financial performance and market reception. The company operates publicly under the NASDAQ symbol ‘KIDS’. It continues to forge on its growth and innovation path
while staying true to its vision of improving the lives of children.
While acknowledging the reputation and achievements of Orthopediatrics Corp, one cannot overlook the exceptional specialization of this company. It stands unique with its requisite focus on pediatric orthopedic care, reflecting its commitment to enhancing the quality of life for this specific demographic, and further validating that ‘kids’ aren’t merely part of their name, but a true representation of their cause.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends

Orthopediatrics Corp. (NASDAQ: KIDS) exhibits strong sentiment across all time horizons, supporting an overweight bias according to AI models. The article provides institutional trading strategies, including position trading, momentum breakout, and risk hedging, with specific entry zones, targets, and stop losses. Multi-timeframe signal analysis also indicates strong support and resistance levels for near-term, mid-term, and long-term horizons.

OrthoPediatrics Corporation reported record Q3 2026 revenue of $72.7 million, a 19% increase year-over-year, driven by strong demand across all business segments and contributions from new product launches. The company raised its full-year revenue guidance to $270-$273 million while maintaining adjusted EBITDA guidance of approximately $25 million, reflecting continued investment in innovation alongside expense discipline and progress towards positive free cash flow. Key growth drivers include the "innovation Super Cycle" with products like 3P hips and Vertiglide, robust international performance, and expansion of the OPSB clinic network, setting up multi-year growth opportunities.
OrthoPediatrics Corp. (Nasdaq: KIDS) announced record financial results for the third quarter of 2026, with total revenue reaching $72.7 million, a 19% increase year-over-year. The company also increased its full-year 2026 revenue guidance to a range of $270.0 million to $273.0 million and achieved positive free cash flow of $1.6 million for the quarter. These results were driven by strong growth in Trauma & Deformity and Scoliosis segments, alongside new product introductions.